Lantheus (NASDAQ:LNTH – Get Free Report) had its price objective lowered by B. Riley from $127.00 to $122.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” ...

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) ...

In trading on Friday, shares of Lantheus Holdings Inc (Symbol: LNTH) crossed below their 200 day moving average of $96.71, changing hands as low as $94.80 per share. Lantheus Holdings Inc shares ...

$LNTH insiders have traded $LNTH stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales. Members of ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

In a regulatory filing, Lantheus ( LNTH) Holdings CFO Robert Marshall Jr. disclosed the sale of 10,000 common shares of the company on March 17 at a price of $100.52 per share. Discover stocks' market ...

LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th, producing sales of over $1 billion for Pylarify during the calendar year. Other products ...

Despite challenges, LNTH has potential for further growth, with promising assets in Alzheimer's and oncology, aiming for a double-digit billion market cap by decade's end. As we can see above ...

Stay updated on market trends for LNTH. Root And ZoomInfo Are Among Top 8 Mid-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio? Top mid-cap stock gainers in past week ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...